Akero Therapeutics, Inc.
AKROHealthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — |
| Operating income | −$285.4M | −$172.9M | −$115.2M | −$100.9M | −$80.2M | −$45.7M |
| Net income | −$252.1M | −$151.8M | −$112.0M | −$100.8M | −$79.2M | −$43.8M |
| Total assets | $825.9M | $580.3M | $356.6M | $195.5M | $273.3M | $138.1M |
| Total liabilities | $75.8M | $45.0M | $30.0M | $26.4M | $14.6M | $9.4M |
| Equity | $750.1M | $535.3M | $326.6M | $169.1M | $258.7M | $128.7M |
| EPS (diluted) | $-3.75 | $-2.89 | $-2.87 | $-2.89 | $-2.52 | $-2.90 |
| Shares out. | 56.3M | 47.0M | 35.0M | 34.8M | 28.6M | 28.6M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2024- Operating margin
- —
- Net margin
- —
- Return on equity
- −33.6%
- Return on assets
- −30.5%
- Return on capital (ROCE)
- −36.3%
- Liabilities / assets
- 9.2%
- Debt / equity
- 0.10×
- Book value / share
- $13.32
- Revenue growth (YoY)
- —
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2024- Altman Z″ (distress)
- 10.61safe
- Accruals / assets
- −2.7%clean
- Piotroski F-Score
- 1/7weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 1 warning● 3 good- Negative operating cash flow
- Conservative leverage (liabilities < 50% of assets)
- Clean earnings (low accruals)
- Altman Z″ in the safe zone
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Clinical trials
ClinicalTrials.gov · ongoing · next readout first- Phase 2Active Not Recruitingreadout ~2023-08-25A Study of Efruxifermin in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH) (Symmetry)
- Phase 3Active Not Recruitingreadout ~2026-03-03A Study Evaluating Efruxifermin in Subjects With Non-invasively Diagnosed Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Nonalcoholic Fatty Liver Disease (NAFLD)/Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
- Phase 3Recruitingreadout ~2030-02A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH
- Phase 3Recruitingreadout ~2032-11A Study Evaluating Efruxifermin in Subjects With Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis
Interventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.
5%+ owners
SEC Schedule 13D / 13G · last 3 yrs- Rtw Investments, LpPassive (13G)Feb 17, 2026
- Janus Henderson Group PlcPassive (13G)Feb 17, 2026
- Deep Track Capital, LpPassive (13G)Feb 13, 2026
- Wellington Management Group LlpPassive (13G)Feb 10, 2026
- Price T Rowe Associates Inc /Md/Passive (13G)Nov 14, 2025
- General Atlantic, L.P.Passive (13G)May 15, 2025
Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| Nov 28, 2025 | 4.2M | 4.0 | -2.8% |
| Nov 14, 2025 | 4.3M | 2.6 | -2.0% |
| Oct 31, 2025 | 4.4M | 2.5 | -24.1% |
| Oct 15, 2025 | 5.8M | 1.0 | -41.6% |
| Sep 30, 2025 | 10.0M | 7.5 | +9.6% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Terminated a material agreement · Completed an acquisition or disposition · Delisting / listing-standard notice · Modified shareholder rights · Change in control · Director / officer change · Amended charter or bylawsDec 9, 2025
- Shareholder vote · Other material eventDec 3, 2025
- Entered a material agreement · Amended charter or bylaws · Other material eventOct 9, 2025
- Terminated a material agreementSep 29, 2025
- Results of operationsAug 8, 2025
- Shareholder voteJun 4, 2025
- Results of operationsMay 12, 2025
- Results of operationsFeb 28, 2025
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗- SCHEDULE 13G/AFeb 17, 2026
- SCHEDULE 13G/AFeb 17, 2026
- SCHEDULE 13G/AFeb 13, 2026
- SCHEDULE 13G/AFeb 10, 2026
- 15-12GDec 19, 2025
- 25-NSEDec 9, 2025
- 4Dec 9, 2025
- 4Dec 9, 2025
- 4Dec 9, 2025
- 4Dec 9, 2025
- 4Dec 9, 2025
- 4Dec 9, 2025
- 4Dec 9, 2025
- 4Dec 9, 2025
- 4Dec 9, 2025
Event-driven situations (1)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.